SAN DIEGO, April 16, 2012 /PRNewswire/ -- ADVENTRX
Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the
Company is a sponsor of and will be presenting at the Martin
Center's 2012 Indiana Statewide Sickle Cell Disease Conference at
the Indiana Landmarks Center in Indianapolis, Indiana on April 20, 2012. The conference seeks to bring
awareness to the continued presence of sickle cell disease (SCD)
and to inform the SCD community about current and proposed
therapies for the disease.
"We are pleased to join with Novartis and Indiana University Health as a gold sponsor of the
Martin Center's conference," stated Brian
M. Culley, Chief Executive Officer of ADVENTRX. "We look
forward to discussing ANX-188 and its potential to treat patients
with sickle cell disease with the research, healthcare and patient
communities' representatives present at the conference."
Martin Center, Inc. is a human services agency dedicated to
aiding and enhancing the lives of those affected by sickle cell
disease and sickle cell trait in Central and Southern Indiana. Its programs include support
and education for sickle cell and other abnormal hemoglobin
conditions.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company focused
on developing proprietary product candidates. The Company's
lead product candidate is ANX-188, a rheologic, antithrombotic and
cytoprotective agent that improves microvascular blood flow and has
potential application in treating a wide range of diseases and
conditions, such as complications arising from sickle cell
disease. We also are developing ANX-514, a novel,
detergent-free formulation of the chemotherapy drug
docetaxel. More information can be found on the Company's web
site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this
press release that are not a description of historical facts are
forward-looking statements that are based on ADVENTRX's current
expectations and assumptions. Such forward-looking statements
include, but are not limited to, statements regarding ADVENTRX's
development plans for ANX-188, including the nature and timing of
future clinical studies, and ANX-188's potential as an effective
treatment for sickle cell disease patients. Among the factors that
could cause or contribute to material differences between
ADVENTRX's actual results and those indicated from the
forward-looking statements are risks and uncertainties inherent in
ADVENTRX's business, including, but are not limited to: the
potential for ADVENTRX to delay, reduce or discontinue current
and/or planned development activities, partner its product
candidates at inopportune times or pursue less expensive but
higher-risk development paths if it is unable to raise sufficient
additional capital as needed; ADVENTRX's ability to obtain
additional funding on a timely basis or on acceptable terms, or at
all; the potential for delays in the commencement or completion of
its planned clinical studies including as a result of difficulties
or delays in completing manufacturing process development
activities and manufacturing clinical trial material; the risk of
suspension or termination of a clinical study including due to lack
of adequate funding; the risk that planned clinical studies of
ADVENTRX's product candidates, including ANX-188, are not
successful and, even if they are successful, that the FDA could
determine they are not sufficient to support an NDAs for the
product candidate; the risk that the FDA does not grant market
approval of ADVENTRX's product candidates, including ANX-188, on a
timely basis, or at all; ADVENTRX's reliance on third parties to
assist in the conduct of important aspects of its product
candidates' development programs, including the manufacture of
clinical trial material, the conduct of clinical studies and
regulatory submissions related to product approval, and that such
third parties may fail to perform as expected; and other risks and
uncertainties more fully described in ADVENTRX's press releases and
periodic filings with the Securities and Exchange Commission.
ADVENTRX's public filings with the Securities and Exchange
Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date when made. ADVENTRX
does not intend to revise or update any forward-looking statement
set forth in this press release to reflect events or circumstances
arising after the date hereof, except as may be required by
law.
SOURCE ADVENTRX Pharmaceuticals, Inc.